The head of the Senate Finance Committee is seeking details from Bristol-Myers Squibb Co. about a decade-old offshore deal that let the pharmaceutical giant cut its tax rate by more than 30 percentage points.
Senator Ron Wyden sent a letter Tuesday to Bristol-Myers CEO Giovanni Caforio asking him to explain a 2012 transaction that shifted the company's intellectual property profits (IP) to Ireland and resulted in reducing its tax rate to -6.9 percent that year, from +24.7 percent the year before.
The Oregon Democrat also asked for details about how the company's tax and legal advisers, accounting firm PwC and law firm White & Case LLP, were involved in the process. Bristol-Myers said in a statement that it has received the letter and will cooperate with Wyden on his request.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world case studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
